A universal platform for TCRα/β removal enables safer and more potent TCR therapies and autoimmune modeling
JCI Insight · 17.11.2026
DOI: 10.1172/jci.insight.201920 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCI Insight, online erschienen am 17.11.2026. Verfasst von Giorgia Zanetti und 16 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH, Juvenile Diabetes Research Foundation, Herbert Irving Cancer Center.
Abstract (Originalsprache)
Adoptive T-cell therapies using tumour-specific T-cell receptors (TCRs) are limited by competition with endogenous receptors, impairing efficacy and posing risks of off-target autoreactivity. Here we present a CRISPR-based platform that selectively eliminates both endogenous TCR-α and -β chains without affecting transgenic TCRs, irrespective of codon optimization. This approach achieves >90% deletion efficiency in Jurkat and primary human T cells, enhancing expression and functional potency of transgenic receptors. Using an HLA-A*02:01-restricted DMF5 TCR, we show that dual TCR ablation boosts antigen-specific activation and cytotoxicity in vitro and enhances tumor clearance in vivo in human immune system (HIS) mice and prevents graft-versus-host disease (GVHD). Targeted locus amplification showed that CRISPR-induced double-strand breaks did not alter lentiviral integration profiles, supporting genomic safety. Extending this approach to four insulin-reactive TCRs demonstrated that endogenous receptor removal increased transduction efficiency and functional activity, with one (1E6) showing selective activation and infiltration of islet grafts (SC-islets) in vivo. This study establishes a universal, safe, and scalable genome-editing platform for generating functionally precise human T cells. By integrating cancer immunotherapy and autoimmune disease modelling within a single framework, it provides a preclinical rationale for dual endogenous TCR removal to improve specificity, safety, and therapeutic efficacy in TCR-based cell therapies.
Förderung
- NIH
- Juvenile Diabetes Research Foundation
- Herbert Irving Cancer Center
- Diabetes Research Center
- Wellcome
- American Diabetes Association (ADA) Postdoctoral Fellowship
- Columbia University Naomi Berrie Diabetes Center Russell Berrie Foundation Fellowship
Zitieren
APA
Zanetti, G., Nikhat, S., Legut, M., Chen, A., Fathi, F., Suek, N., Teteloshvili, N., Li, H. W., Ding, X., Traum, D., Kaestner, K. H., Hoang, R. E., Sewell, A. K., Parent, A. V., Creusot, R. J., Sykes, M., & Khosravi-Maharlooei, M. (2026). A universal platform for TCRα/β removal enables safer and more potent TCR therapies and autoimmune modeling. JCI Insight. https://doi.org/10.1172/jci.insight.201920
Vancouver
Zanetti G, Nikhat S, Legut M, Chen A, Fathi F, Suek N, et al. A universal platform for TCRα/β removal enables safer and more potent TCR therapies and autoimmune modeling. JCI Insight. 2026. doi:10.1172/jci.insight.201920
BibTeX
@article{Zanetti2026,
author = {Zanetti, Giorgia and Nikhat, Sameena and Legut, Mateusz and Chen, Austin and Fathi, Farshid and Suek, Nathan and Teteloshvili, Nato and Li, Hao Wei and Ding, Xiaolan and Traum, Daniel and Kaestner, Klaus H. and Hoang, Ryan E. and Sewell, Andrew K. and Parent, Audrey V. and Creusot, Remi J. and Sykes, Megan and Khosravi-Maharlooei, Mohsen},
title = {A universal platform for TCRα/β removal enables safer and more potent TCR therapies and autoimmune modeling},
journal = {JCI Insight},
year = {2026},
doi = {10.1172/jci.insight.201920}
}
EUVIMED